The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma. The study investigators from City of Hope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results